{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:18:58Z","timestamp":1787008738073,"version":"build-2736575974"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"15","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biomarkers and Oxidative Stress awarded USA","award":["US9638699B2"],"award-info":[{"award-number":["US9638699B2"]}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Whilst we continue to wrestle with the immense challenge of implementing equitable access to established evidence-based treatments, substantial gaps remain in our pharmacotherapy armament for common forms of cardiovascular disease including coronary and peripheral arterial disease, heart failure, hypertension, and arrhythmia. We need to continue to invest in the development of new approaches for the discovery, rigorous assessment, and implementation of new therapies. Currently, the time and cost to progress from lead compound\/product identification to the clinic, and the success rate in getting there reduces the incentive for industry to invest, despite the enormous burden of disease and potential size of market. There are tremendous opportunities with improved phenotyping of patients currently batched together in syndromic \u2018buckets\u2019. Use of advanced imaging and molecular markers may allow stratification of patients in a manner more aligned to biological mechanisms that can, in turn, be targeted by specific approaches developed using high-throughput molecular technologies. Unbiased \u2018omic\u2019 approaches enhance the possibility of discovering completely new mechanisms in such groups. Furthermore, advances in drug discovery platforms, and models to study efficacy and toxicity more relevant to the human disease, are valuable. Re-imagining the relationships among discovery, translation, evaluation, and implementation will help reverse the trend away from investment in the cardiovascular space, establishing innovative platforms and approaches across the full spectrum of therapeutic development.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehab068","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T15:30:33Z","timestamp":1612539033000},"page":"1464-1475","source":"Crossref","is-referenced-by-count":43,"title":["A call to action for new global approaches to cardiovascular disease drug solutions"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5080-6083","authenticated-orcid":false,"given":"Gemma A","family":"Figtree","sequence":"first","affiliation":[{"name":"Kolling Institute, Royal North Shore Hospital, University of Sydney , Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Broadfoot","sequence":"additional","affiliation":[{"name":"Clinical Committee, National Heart Foundation of Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6801-1617","authenticated-orcid":false,"given":"Barbara","family":"Casadei","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford , Oxford, UK"},{"name":"NIHR Oxford Biomedical Research Centre , Oxford, UK"},{"name":"British Heart Foundation Centre of Research Excellence , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0231-3724","authenticated-orcid":false,"given":"Robert","family":"Califf","sequence":"additional","affiliation":[{"name":"Verily"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-8846","authenticated-orcid":false,"given":"Filippo","family":"Crea","sequence":"additional","affiliation":[{"name":"Catholic University , Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8556-9738","authenticated-orcid":false,"given":"Grant R","family":"Drummond","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Biology and Disease Research; and Department of Physiology, Anatomy and Microbiology, La Trobe University , Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0011-6164","authenticated-orcid":false,"given":"Jane E","family":"Freedman","sequence":"additional","affiliation":[{"name":"Cardiovascular Research, University of Massachusetts Medical School , MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz J","family":"Guzik","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow , UK and Jagiellonian University Collegium Medicum, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Harrison","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Vanderbilt University School of Medicine , Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J","family":"Hausenloy","sequence":"additional","affiliation":[{"name":"Signature Research Program in Cardiovascular & Metabolic Disorders Program, Duke-National University of Singapore NUS Medical School , Singapore"},{"name":"National Heart Research Institute Singapore, National Heart Centre , Singapore"},{"name":"Yong Loo Lin School of Medicine, National University Singapore , Singapore"},{"name":"The Hatter Cardiovascular Institute, University College London , London, UK"},{"name":"Cardiovascular Research Center, College of Medical and Health Sciences, Asia University , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5379-1614","authenticated-orcid":false,"given":"Joseph A","family":"Hill","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern , Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard University , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-0458","authenticated-orcid":false,"given":"Bronwyn A","family":"Kingwell","sequence":"additional","affiliation":[{"name":"CSL Limited , Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S P","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore and Duke-National University of Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calum A","family":"MacRae","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1366-7958","authenticated-orcid":false,"given":"Frank","family":"Misselwitz","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceuticals Division , Wuppertal, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5024-7085","authenticated-orcid":false,"given":"Tetsuji","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University , Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8610-0058","authenticated-orcid":false,"given":"Rebecca H","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus) , Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8215-6567","authenticated-orcid":false,"given":"Maciej","family":"Tomaszewski","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health and Manchester University NHS Foundation Trust, University of Manchester , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-8041","authenticated-orcid":false,"given":"Joseph C","family":"Wu","sequence":"additional","affiliation":[{"name":"Stanford Cardiovascular Institute , Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Xiao","sequence":"additional","affiliation":[{"name":"Cardiac Regeneration and Ageing Lab, Institute of Cardiovascular Sciences, School of Life Sciences, Shanghai University , Shanghai, 200444, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM CIC 1493, INI CRCT, CHRU Nancy , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"2022102612473482900_ehab068-B1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/eurheartj\/ehz859","article-title":"European Society of Cardiology: cardiovascular disease statistics 2019","volume":"41","author":"Timmis","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612473482900_ehab068-B2","first-page":"e139","article-title":"Heart disease and stroke statistics\u20142020 update: a report from the American Heart Association","volume":"141","author":"Virani Salim","year":"2020","journal-title":"Circulation"},{"key":"2022102612473482900_ehab068-B3","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102612473482900_ehab068-B4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jacbts.2016.03.012","article-title":"Temporal trends and factors associated with cardiovascular drug development, 1990 to 2012","volume":"1","author":"Hwang","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"2022102612473482900_ehab068-B5","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2015.03.016","article-title":"Cardiovascular drug development: is it dead or just hibernating?","volume":"65","author":"Fordyce","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022102612473482900_ehab068-B6","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1056\/NEJMp1402114","article-title":"Drug development and FDA approval, 1938-2013","volume":"370","author":"Darrow","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102612473482900_ehab068-B7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrd3405","article-title":"The productivity crisis in pharmaceutical R&D","volume":"10","author":"Pammolli","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2022102612473482900_ehab068-B8","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1161\/CIRCULATIONAHA.117.029870","article-title":"Acute coronary syndromes: the way forward from mechanisms to precision treatment","volume":"136","author":"Crea","year":"2017","journal-title":"Circulation"},{"key":"2022102612473482900_ehab068-B9","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.118.031373","article-title":"Reappraisal of ischemic heart disease","volume":"138","author":"Kaski","year":"2018","journal-title":"Circulation"},{"key":"2022102612473482900_ehab068-B10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jacbts.2016.07.003","article-title":"Resourcing drug development commensurate with its public health importance: the road ahead","volume":"1","author":"Fiuzat","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"2022102612473482900_ehab068-B11","year":"2020"},{"key":"2022102612473482900_ehab068-B12","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1177\/2047487317720287","article-title":"Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors","volume":"24","author":"Vernon","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"2022102612473482900_ehab068-B13","doi-asserted-by":"crossref","first-page":"e013296","DOI":"10.1161\/JAHA.119.013296","article-title":"ST-Segment-Elevation Myocardial Infarction (STEMI) patients without standard modifiable cardiovascular risk factors-how common are they, and what are their outcomes?","volume":"8","author":"Vernon","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2022102612473482900_ehab068-B14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/2047487317706586","article-title":"Coronary artery disease: risk stratification and patient selection for more aggressive secondary prevention","volume":"24","author":"Schiele","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"2022102612473482900_ehab068-B15","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102612473482900_ehab068-B16","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102612473482900_ehab068-B17","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.032178","article-title":"Addressing acute coronary syndromes: new challenges and opportunities after the CANTOS Trial (Canakinumab Anti-inflammatory Thrombosis Outcomes Study)","volume":"137","author":"Crea","year":"2018","journal-title":"Circulation"},{"key":"2022102612473482900_ehab068-B18","doi-asserted-by":"crossref","first-page":"e12488","DOI":"10.1111\/micc.12488","article-title":"Utilizing state-of-the-art \"omics\" technology and bioinformatics to identify new biological mechanisms and biomarkers for coronary artery disease","volume":"26","author":"Vernon","year":"2019","journal-title":"Microcirculation"},{"key":"2022102612473482900_ehab068-B19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng.2480","article-title":"Large-scale association analysis identifies new risk loci for coronary artery disease","volume":"45","author":"Deloukas","year":"2013","journal-title":"Nat Genet"},{"key":"2022102612473482900_ehab068-B20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nchem.217","article-title":"The rise of fragment-based drug discovery","volume":"1","author":"Murray","year":"2009","journal-title":"Nat Chem"},{"key":"2022102612473482900_ehab068-B21","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/cvr\/cvz183","article-title":"New opportunities for targeting redox dysregulation in cardiovascular disease","volume":"116","author":"Bubb","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2022102612473482900_ehab068-B22","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1093\/eurheartj\/ehaa229","article-title":"From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases","volume":"41","author":"Landmesser","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612473482900_ehab068-B23","year":"2020"},{"key":"2022102612473482900_ehab068-B24","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMra2000317","article-title":"Atherosclerotic plaque healing","volume":"383","author":"Vergallo","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102612473482900_ehab068-B25","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMra061889","article-title":"Coronary microvascular dysfunction","volume":"356","author":"Camici","year":"2007","journal-title":"N Engl J Med"},{"key":"2022102612473482900_ehab068-B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0323-2","article-title":"Heart failure with preserved ejection fraction: present status and future directions","volume":"51","author":"Yoon","year":"2019","journal-title":"Exp Mol Med"},{"key":"2022102612473482900_ehab068-B27","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1161\/CIRCULATIONAHA.119.040057","article-title":"Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus","volume":"139","author":"Figtree","year":"2019","journal-title":"Circulation"},{"key":"2022102612473482900_ehab068-B28","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"2022102612473482900_ehab068-B29","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102612473482900_ehab068-B30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s12265-017-9756-y","article-title":"Precision medicine for heart failure with preserved ejection fraction: an overview","volume":"10","author":"Shah","year":"2017","journal-title":"J Cardiovasc Transl Res"},{"key":"2022102612473482900_ehab068-B31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2022102612473482900_ehab068-B32","doi-asserted-by":"crossref","first-page":"e028649","DOI":"10.1136\/bmjopen-2018-028649","article-title":"Biobanking for discovery of novel cardiovascular biomarkers using imaging-quantified disease burden: protocol for the longitudinal, prospective, BioHEART-CT cohort study","volume":"9","author":"Kott","year":"2019","journal-title":"BMJ Open"},{"key":"2022102612473482900_ehab068-B33","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1124\/pr.112.007252","article-title":"Pharmacogenetics and cardiovascular disease\u2013implications for personalized medicine","volume":"65","author":"Johnson","year":"2013","journal-title":"Pharmacol Rev"},{"key":"2022102612473482900_ehab068-B34","year":"2008"},{"key":"2022102612473482900_ehab068-B35","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jacc.2012.03.074","article-title":"Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection","volume":"60","author":"Celermajer","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2022102612473482900_ehab068-B36","doi-asserted-by":"crossref","first-page":"e1499","DOI":"10.1371\/journal.pntd.0001499","article-title":"Neglected tropical diseases as hidden causes of cardiovascular disease","volume":"6","author":"Moolani","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2022102612473482900_ehab068-B37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/FJC.0b013e318247f642","article-title":"Induced pluripotent stem cells as a disease modeling and drug screening platform","volume":"60","author":"Ebert","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022102612473482900_ehab068-B38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax9276","article-title":"Clinical trial in a dish using iPSCs shows lovastatin improves endothelial dysfunction and cellular cross-talk in LMNA cardiomyopathy","volume":"12","author":"Sayed","year":"2020","journal-title":"Sci Transl Med"},{"key":"2022102612473482900_ehab068-B39","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCRESAHA.119.315491","article-title":"Generation of quiescent cardiac fibroblasts from human induced pluripotent stem cells for in vitro modeling of cardiac fibrosis","volume":"125","author":"Zhang","year":"2019","journal-title":"Circ Res"},{"key":"2022102612473482900_ehab068-B40","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1038\/s41598-017-06385-8","article-title":"Cardiac spheroids as promising in vitro models to study the human heart microenvironment","volume":"7","author":"Polonchuk","year":"2017","journal-title":"Sci Rep"},{"key":"2022102612473482900_ehab068-B41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1089\/ten.tec.2017.0247","article-title":"Development of in vitro drug-induced cardiotoxicity assay by using three-dimensional cardiac tissues derived from human induced pluripotent stem cells","volume":"24","author":"Takeda","year":"2018","journal-title":"Tissue Eng Part C Methods"},{"key":"2022102612473482900_ehab068-B42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0305-0491(82)90252-8","article-title":"Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species","volume":"71","author":"Ha","year":"1982","journal-title":"Comp Biochem Physiol B"},{"key":"2022102612473482900_ehab068-B43","first-page":"433","article-title":"Differences in innate immune response between man and mouse","volume":"34","author":"Zschaler","year":"2014","journal-title":"Crit Rev Immunol"},{"key":"2022102612473482900_ehab068-B44","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pharmthera.2013.10.007","article-title":"Small and large animal models in cardiac contraction research: advantages and disadvantages","volume":"141","author":"Milani-Nejad","year":"2014","journal-title":"Pharmacol Ther"},{"key":"2022102612473482900_ehab068-B45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cmet.2016.08.006","article-title":"Never waste a good crisis: confronting reproducibility in translational research","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"key":"2022102612473482900_ehab068-B46","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.jacc.2019.03.020","article-title":"Translating cardioprotection for patient benefit: the EU-CARDIOPROTECTION COST Action","volume":"73","author":"Hausenloy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102612473482900_ehab068-B47","doi-asserted-by":"crossref","first-page":"H733","DOI":"10.1152\/ajpheart.00339.2017","article-title":"Guidelines for measuring cardiac physiology in mice","volume":"314","author":"Lindsey","year":"2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2022102612473482900_ehab068-B48","doi-asserted-by":"crossref","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"Percie Du Sert","year":"2020","journal-title":"PLoS Biol"},{"key":"2022102612473482900_ehab068-B49","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/STROKEAHA.118.023927","article-title":"Stroke treatment academic industry roundtable X: brain cytoprotection therapies in the reperfusion era","volume":"50","author":"Savitz","year":"2019","journal-title":"Stroke"},{"key":"2022102612473482900_ehab068-B50","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12968-018-0484-5","article-title":"Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I\u2014analytical validation and clinical qualification","volume":"20","author":"Puntmann","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"key":"2022102612473482900_ehab068-B51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","article-title":"Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study","volume":"11","author":"Vaidya","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022102612473482900_ehab068-B52","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"},{"key":"2022102612473482900_ehab068-B53","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacc.2020.05.060","article-title":"Improving the design of future PCI trials for stable coronary artery disease: JACC state-of-the-art review","volume":"76","author":"Marquis-Gravel","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102612473482900_ehab068-B54","doi-asserted-by":"crossref","first-page":"m139","DOI":"10.1136\/bmj.m139","article-title":"Inclisiran: UK to roll out new cholesterol lowering drug from next year","volume":"368","author":"Iacobucci","year":"2020","journal-title":"BMJ"},{"key":"2022102612473482900_ehab068-B55","year":"2020"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/15\/1464\/46644526\/ehab068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/15\/1464\/46644526\/ehab068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T08:49:50Z","timestamp":1666774190000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/15\/1464\/6224948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":55,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2021,4,13]]},"published-print":{"date-parts":[[2021,4,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab068","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,14]]},"published":{"date-parts":[[2021,4,13]]}}}